Drake Anthony Russell

Dr. Drake Anthony Russell

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2023 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
DRDrake Anthony Russell
Drake Anthony Russell
MCMarvin K. Chau
Marvin K. Chau
YSYuanyuan Shi
Yuanyuan Shi
ILIan N. Levasseur
Ian N. Levasseur
BMBenjamin J. Maldonato
Benjamin J. Maldonato
Rheem TotahRheem Totah
Rheem Totah
S-Methylation of drugs containing thiol-moieties often alters their activity and results in detoxification. Historically, scientists attributed methylation of exogenous aliphatic and phenolic thiols to a putative S-adenosyl-L-methionine dependent membrane-associated phase II enzyme known as thiol methyltransferase (TMT). TMT has a broad substrate specificity and methylates the thiol metabolite of spironolactone, mertansine, ziprasidone, captopril, and the active metabolites of the thienopyridine pro-drugs, clopidogrel, and prasugrel. Despite TMT9s role in the S-methylation of clinically relevant drugs, the enzyme(s) responsible for this activity remained unknown. We recently identified methyltransferase-like protein 7B (METTL7B) as an alkyl thiol-methyltransferase. METTL7B is an endoplasmic-reticulum-associated protein with similar biochemical properties and substrate specificity to TMT. Yet, the historic TMT inhibitor, 2,3-dichloro-α-methylbenzylamine (DCMB), does not inhibit METTL7B, indicating that multiple enzymes contribute to TMT activity. Here we report that methyltransferase-like protein 7A (METTL7A), an uncharacterized member of the METTL7 family, is also a thiol-methyltransferase. METTL7A exhibits similar biochemical properties to METTL7B and TMT, including inhibition by DCMB (IC50 1.2 µM). Applying quantitative proteomics to human liver microsomes and gene modulation experiments in HepG2 and HeLa cells, we determined that TMT activity correlates closely with METTL7A and METTL7B protein levels. Furthermore, purification of a novel His-GST-tagged recombinant protein and subsequent activity experiments prove that METTL7A can selectively methylate exogenous thiol-containing substrates, including 7α-thiospironolactone, dithiothreitol, 4-chlorothiophenol, and mertansine. We conclude that the METTL7 family encodes for two enzymes, METTL7A and METTL7B, which we have renamed TMT1A and TMT1B, respectively, that are responsible for TMT activity in human liver microsomes. Significance Statement We identified METTL7A (TMT1A) and METTL7B (TMT1B) as the enzymes responsible for the microsomal alkyl thiol methyltransferase (TMT) activity. These are the first two enzymes directly associated with microsomal TMT activity. S-Methylation of commonly prescribed thiol-containing drugs alters their pharmacological activity and/or toxicity and identifying the enzymes responsible for this activity will improve our understanding of the DMPK properties of alkyl- or phenolic-thiol-containing therapeutics.

27 December 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
RRRobert W. Robey
Robert W. Robey
CFChristina M. Fitzsimmons
Christina M. Fitzsimmons
WGWilfried M. Guiblet
Wilfried M. Guiblet
WFWilliam J.E. Frye
William J.E. Frye
JDJosé M. González Dalmasy
José M. González Dalmasy
PBPedro J. Batista
Pedro J. Batista
Histone deacetylase inhibitors (HDACi) are part of a growing class of epigenetic therapies used for the treatment of cancer. Although HDACis are effective in the treatment of T-cell lymphomas, treatment of solid tumors with this class of drugs has not been successful. Overexpression of the multidrug resistance protein P-glycoprotein (P-gp), encoded by ABCB1, is known to confer resistance to the HDACi romidepsin in vitro, yet increased ABCB1 expression has not been associated with resistance in patients, suggesting that other mechanisms of resistance arise in the clinic. To identify alternative mechanisms of resistance to romidepsin, we selected MCF-7 breast cancer cells with romidepsin in the presence of the P-gp inhibitor verapamil to reduce the likelihood of P-gp-mediated resistance. The resulting cell line, MCF-7 DpVp300, does not express P-gp and was found to be selectively resistant to romidepsin but not to other HDACis such as belinostat, panobinostat, or vorinostat. RNA-sequencing analysis revealed upregulation of the mRNA coding for the putative methyltransferase, METTL7A, whose paralog, METTL7B, was previously shown to methylate thiol groups on hydrogen sulfide and captopril. As romidepsin has a thiol as the zinc-binding moiety, we hypothesized that METTL7A could inactivate romidepsin and other thiol-based HDACis via methylation of the thiol group. We demonstrate that expression of METTL7A or METTL7B confers resistance to thiol-based HDACis and that both enzymes are capable of methylating thiol-containing HDACis. We thus propose that METTL7A and METTL7B confer resistance to thiol-based HDACis by methylating and inactivating the zinc-binding thiol.

27 June 2024 in Catalysis Science & Technology
Verified
Journal Article
Closed access
PDF file
KHKurt L. Harris
Kurt L. Harris
YZYichi Zhang
Yichi Zhang
JYJade Yang
Jade Yang
MZMaxwell B. Zeigler
Maxwell B. Zeigler
RTRaine E. S. Thomson
Raine E. S. Thomson
EGElizabeth M. J. Gillam
Elizabeth M. J. Gillam
Biopolymers produced from plant sources offer sustainable alternatives to plastics derived from petrochemicals. Hydroxylated fatty acids (OHFAs) can be readily polymerized to form polyesters. The CYP4 family of cytochrome P450 monooxygenases are potential biocatalysts for fatty acid (FA) ω-hydroxylation, but existing CYP4 enzymes are limited by their inherently low thermostability. Here we resurrected ancestral FA hydroxylases belonging to the CYP4ABTXZ clade, that were significantly more thermostable than the corresponding extant forms with 10T50 values up to 68 °C. All ancestors were active towards C12–C20 FAs, but differed in chain length preference and hydroxylation regioselectivity. While extant CYP4A and CYP4B forms preferentially hydroxylate the terminal (ω) carbon, the ancestors showed less specificity for the ω-position for C12–C18 FAs overall. All ancestors were more active towards arachidonic acid (C20) than the extant forms tested, preferring hydroxylation at the ω-position. Reactions could be made more cost effective by using O2 surrogates, obviating the need for O2, NADPH or a co-expressed redox partner. These enzymes will serve as robust templates for the further engineering of stable FA hydroxlases with activity towards different FAs and alkyl chain positions to produce precursors for synthetic fibres with desired properties.

7 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RRRobert W. Robey
Robert W. Robey
CFChristina M. Fitzsimmons
Christina M. Fitzsimmons
WGWilfried M. Guiblet
Wilfried M. Guiblet
WFWilliam J.E. Frye
William J.E. Frye
JDJosé M. González Dalmasy
José M. González Dalmasy
PBPedro J. Batista
Pedro J. Batista
Histone deacetylase inhibitors (HDACis) are part of a growing class of epigenetic therapies used for the treatment of cancer. While elevated levels of the efflux pump P-gp are associated with in vitro resistance to romidepsin, this mechanism does not translate to the clinic. We developed a romidepsin-resistant cell line with a resistance mechanism independent of P-gp function that acts upstream of the deacetylation process. We found that expression of the methyltransferase METTL7A is necessary for resistance, and that expression of METTL7A in naïve cells can drive resistance to thiol-containing HDACis. We demonstrate that METTL7A can methylate romidesin in vitro and that the ability of METTL7A to drive resistance to thiol-containing HDACis can be blocked by the methyltransferase inhibitor DCMB. Our data supports a model whereby exposure of cells to romidepsin selects for upregulation of the methyltransferase METTL7A, which in turn modifies the zinc-binding thiol, inactivating the drug.

19 December 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
DRDrake Anthony Russell
Drake Anthony Russell
CSCarson Stafford
Carson Stafford
Rheem TotahRheem Totah
Rheem Totah
Background: Thiopurine methyltransferase (TPMT) plays a crucial role in the detoxification of thiopurine drugs, including the antimetabolites azathioprine and 6-mercaptopurine (6-MP) used to treat autoimmune diseases and various cancers. These drugs interfere with DNA synthesis by inhibiting the production of purine-containing nucleotides, leading to the death of rapidly dividing cells. TPMT inactivates thiopurine drugs by methylating at the thiol group. The activity of TPMT can vary significantly between individuals, and its activity is impacted by co-administered drugs, altering the effectiveness and toxicity of thiopurine drugs. TPMT is inhibited by many drugs that are co-administered to treat symptoms associated with diseases treated with thiopurines. For example, aspirin and other anti-inflammatory drugs, including olsalazine, sulfasalazine, and balsalazide, inhibit TPMT. The impact of TPMT genotypes on its methylating activity is well defined, and genotyping patients to identify TPMT metabolizer status is common clinical practice. Unfortunately, there has been no concerted effort to comprehensively identify drugs on the market that impact TPMT activity. The inhibition of TPMT by co-administered drugs could in part be responsible for idiosyncratic toxicities associated with thiopurine drug therapy. Methods: Here, we report a facile approach to produce large quantities of recombinant TPMT and a high-throughput assay that utilizes the shift in absorbance due to the methylation of thiopurines to report on TPMT activity. Results and Conclusions: With purified TPMT on hand and the absorbance activity assay, we confirmed several compounds that inhibit TPMT, and the results were comparable to a mass spectral assay that measured 6-MP methylation. Understanding the impact of co-administered drugs on TPMT activity will improve the safety and efficacy of thiopurine-based treatment regimens.

13 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DRDrake Anthony Russell
Drake Anthony Russell
MCMarvin K. Chau
Marvin K. Chau
YSYuanyuan Shi
Yuanyuan Shi
BMBenjamin J. Maldonato
Benjamin J. Maldonato
Rheem TotahRheem Totah
Rheem Totah
S -Methylation of drugs containing thiol-moieties often alters their activity and results in detoxification. Historically, scientists attributed methylation of exogenous aliphatic and phenolic thiols to a putative S- adenosyl-L-methionine dependent membrane-associated phase II enzyme known as thiol methyltransferase (TMT). TMT has a broad substrate specificity and methylates the thiol metabolite of spironolactone, mertansine, ziprasidone, captopril, and the active metabolites of the thienopyridine pro-drugs, clopidogrel, and prasugrel. Despite TMT’s role in the S- methylation of clinically relevant drugs, the enzyme(s) responsible for this activity remained unknown. We recently identified methyltransferase-like protein 7B (METTL7B) as an alkyl thiol-methyltransferase. METTL7B is an endoplasmic-reticulum-associated protein with similar biochemical properties and substrate specificity to TMT. Yet, the historic TMT inhibitor, 2,3-dichloro-α-methylbenzylamine (DCMB), has no effect on the activity of METTL7B, indicating that multiple enzymes contribute to TMT activity. Here we report that methyltransferase-like protein 7A (METTL7A), an uncharacterized member of the METTL7 family, also acts as a thiolmethyltransferase. METTL7A exhibits similar biochemical properties to TMT, including inhibition by DCMB (IC50 1.2 µM). Applying quantitative proteomics to human liver microsomes and gene modulation experiments in HepG2 and HeLa cells, we determined that TMT activity correlates closely with METTL7A and METTL7B protein levels. Furthermore, purification of a novel His-GST-tagged recombinant protein and subsequent activity experiments prove that METTL7A can selectively methylate exogenous thiol-containing substrates, including 7α-thiospironolactone, dithiothreitol, 4-chlorothiophenol, and mertansine. We conclude that the METTL7 family encodes for two enzymes, METTL7A and METTL7B, which we have renamed TMT1A1 and TMT1B1, respectively, that are responsible for TMT activity in liver microsomes. Significance Statement: We identified METTL7A (TMT1A1) and METTL7B (TMT1B1) as the enzymes responsible for the microsomal alkyl thiol methyltransferase activity. These are the first two enzymes directly associated with microsomal TMT activity. S- Methylation of many commonly prescribed thiol-containing drugs alters their pharmacological activity and/or toxicity, and identifying the enzymes responsible, will improve our understanding of the DMPK properties of alkyl- or phenolic-thiol-containing therapeutics. Visual